39086469|t|Novel drug treatments for pain in advanced cancer and serious illness: a focus on neuropathic pain and chemotherapy-induced peripheral neuropathy.
39086469|a|Drugs that are commercially available but have novel mechanisms of action should be explored as analgesics. This review will discuss haloperidol, miragabalin, palmitoylethanolamide (PEA), and clonidine as adjuvant analgesics or analgesics. Haloperidol is a sigma-1 receptor antagonist. Under stress and neuropathic injury, sigma-1 receptors act as a chaperone protein, which downmodulates opioid receptor activities and opens several ion channels. Clinically, there is only low-grade evidence that haloperidol improves pain when combined with morphine, methadone, or tramadol in patients who have cancer, pain from fibrosis, radiation necrosis, or neuropathic pain. Miragabalin is a gabapentinoid approved for the treatment of neuropathic pain in Japan since 2019. In randomized trials, patients with diabetic neuropathy have responded to miragabalin. Its long binding half-life on the calcium channel subunit may provide an advantage over other gabapentinoids. PEA belongs to a group of endogenous bioactive lipids called ALIAmides (autocoid local injury antagonist amides), which have a sense role in modulating numerous biological processes in particular non-neuronal neuroinflammatory responses to neuropathic injury and systemic inflammation. Multiple randomized trials and meta-analyses have demonstrated PEA's effectiveness in reducing pain severity arising from diverse pain phenotypes. Clonidine is an alpha2 adrenoceptor agonist and an imidazoline2 receptor agonist, which is U.S. Federal Drug Administration approved for attention deficit hyperactivity disorder in children, Tourette's syndrome, adjunctive therapy for cancer-related pain, and hypertension. Clonidine activation at alpha2 adrenoceptors causes downstream activation of inhibitory G-proteins (Gi/Go), which inhibits cyclic Adenosine monophosphate (AMP) production and hyperpolarizes neuron membranes, thus reducing allodynia. Intravenous clonidine has been used in terminally ill patients with poorly controlled symptoms, in particular pain and agitation.
39086469	26	30	pain	Disease	MESH:D010146
39086469	43	49	cancer	Disease	MESH:D009369
39086469	82	98	neuropathic pain	Disease	MESH:D009437
39086469	124	145	peripheral neuropathy	Disease	MESH:D010523
39086469	280	291	haloperidol	Chemical	MESH:D006220
39086469	293	304	miragabalin	Chemical	-
39086469	306	327	palmitoylethanolamide	Chemical	MESH:C005958
39086469	329	332	PEA	Chemical	MESH:C005958
39086469	339	348	clonidine	Chemical	MESH:D003000
39086469	387	398	Haloperidol	Chemical	MESH:D006220
39086469	450	468	neuropathic injury	Disease	MESH:D009437
39086469	645	656	haloperidol	Chemical	MESH:D006220
39086469	666	670	pain	Disease	MESH:D010146
39086469	690	698	morphine	Chemical	MESH:D009020
39086469	700	709	methadone	Chemical	MESH:D008691
39086469	714	722	tramadol	Chemical	MESH:D014147
39086469	726	734	patients	Species	9606
39086469	744	750	cancer	Disease	MESH:D009369
39086469	752	756	pain	Disease	MESH:D010146
39086469	762	770	fibrosis	Disease	MESH:D005355
39086469	772	790	radiation necrosis	Disease	MESH:D011832
39086469	795	811	neuropathic pain	Disease	MESH:D009437
39086469	813	824	Miragabalin	Chemical	-
39086469	830	843	gabapentinoid	Chemical	-
39086469	874	890	neuropathic pain	Disease	MESH:D009437
39086469	934	942	patients	Species	9606
39086469	948	967	diabetic neuropathy	Disease	MESH:D003929
39086469	986	997	miragabalin	Chemical	-
39086469	1093	1107	gabapentinoids	Chemical	-
39086469	1109	1112	PEA	Chemical	MESH:C005958
39086469	1146	1162	bioactive lipids	Chemical	-
39086469	1170	1179	ALIAmides	Chemical	-
39086469	1214	1220	amides	Chemical	MESH:D000577
39086469	1318	1335	neuroinflammatory	Disease	MESH:D000090862
39086469	1349	1367	neuropathic injury	Disease	MESH:D009437
39086469	1381	1393	inflammation	Disease	MESH:D007249
39086469	1458	1461	PEA	Chemical	MESH:C005958
39086469	1490	1494	pain	Disease	MESH:D010146
39086469	1525	1529	pain	Disease	MESH:D010146
39086469	1542	1551	Clonidine	Chemical	MESH:D003000
39086469	1679	1719	attention deficit hyperactivity disorder	Disease	MESH:D001289
39086469	1733	1752	Tourette's syndrome	Disease	MESH:D005879
39086469	1777	1783	cancer	Disease	MESH:D009369
39086469	1792	1796	pain	Disease	MESH:D010146
39086469	1802	1814	hypertension	Disease	MESH:D006973
39086469	1816	1825	Clonidine	Chemical	MESH:D003000
39086469	1939	1969	cyclic Adenosine monophosphate	Chemical	MESH:D000242
39086469	1971	1974	AMP	Chemical	MESH:D000249
39086469	2038	2047	allodynia	Disease	MESH:D006930
39086469	2061	2070	clonidine	Chemical	MESH:D003000
39086469	2103	2111	patients	Species	9606
39086469	2159	2163	pain	Disease	MESH:D010146
39086469	2168	2177	agitation	Disease	MESH:D011595
39086469	Association	MESH:C005958	MESH:D009437
39086469	Negative_Correlation	MESH:D003000	MESH:D009369
39086469	Negative_Correlation	MESH:D008691	MESH:D010146
39086469	Negative_Correlation	MESH:D014147	MESH:D010146
39086469	Negative_Correlation	MESH:D003000	MESH:D011595
39086469	Association	MESH:C005958	MESH:D000090862
39086469	Negative_Correlation	MESH:D006220	MESH:D010146
39086469	Negative_Correlation	MESH:D006220	MESH:D011832
39086469	Negative_Correlation	MESH:D003000	MESH:D001289
39086469	Negative_Correlation	MESH:D003000	MESH:D006973
39086469	Negative_Correlation	MESH:D000249	MESH:D003000
39086469	Negative_Correlation	MESH:D003000	MESH:D010146
39086469	Negative_Correlation	MESH:D003000	MESH:D005879
39086469	Negative_Correlation	MESH:D006220	MESH:D005355
39086469	Negative_Correlation	MESH:D003000	MESH:D006930
39086469	Cotreatment	MESH:D006220	MESH:D009020
39086469	Association	MESH:D000577	MESH:D007249
39086469	Negative_Correlation	MESH:D009020	MESH:D010146
39086469	Negative_Correlation	MESH:D000242	MESH:D003000
39086469	Negative_Correlation	MESH:D008691	MESH:D009369
39086469	Cotreatment	MESH:D006220	MESH:D008691
39086469	Negative_Correlation	MESH:C005958	MESH:D010146
39086469	Cotreatment	MESH:D006220	MESH:D014147
39086469	Association	MESH:C005958	MESH:D007249
39086469	Negative_Correlation	MESH:D009020	MESH:D009437
39086469	Negative_Correlation	MESH:D006220	MESH:D009437

